Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - A pilot study

Transplant International

Volumn 26, Issue 5, 2013, Pages 552-561

  Hautz, Theresa ^a   Krapf, Christoph ^a   Grahammer, Johanna ^a   Zelger, Bettina ^b   Hickethier, Tilman ^a   Seger, Christoph ^c   Eberhart, Nadine ^a   Wallner, Christoph ^a   Messner, Franka ^a   Kotsch, Katja ^a   Griesmacher, Andrea ^c   Brandacher, Gerald ^a,d   Lee, Wp Andrew ^d   Margreiter, Raimund ^a   Pratschke, Johann ^a   Glossmann, Hartmut ^e   Schneeberger, Stefan ^a,d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c Central Institute for Medical and Chemical Laboratory Diagnostics   (Austria)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Correolide C; effector memory T cells; Kv1.3 channel blocker; skin rejection; targeted therapy; vascularized composite allotransplantation

Indexed keywords

CORREOLIDE C; IMMUNOSUPPRESSIVE AGENT; L 000778262; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPOSITE SKIN GRAFT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; EFFECTOR CELL; EPIDERMIS; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN ALLOGRAFT; SKIN INFILTRATE; SKIN TRANSPLANTATION; SPLEEN; TRANSPLANTATION TOLERANCE;

ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HINDLIMB; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KV1.3 POTASSIUM CHANNEL; MALE; PILOT PROJECTS; POTASSIUM CHANNEL BLOCKERS; RATS; RATS, INBRED BN; RATS, INBRED LEW; SKIN TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS; TRITERPENES;

EID: 84876464461     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12080     Document Type: Article

References (41)

1. Schneeberger S, Ninkovic M, Piza-Katzer H, et al,. Status 5 years after bilateral hand transplantation. Am J Transplant 2006; 6: 834.
2. Schneeberger S, Ninkovic M, Gabl M, et al,. First forearm transplantation: outcome at 3 years. Am J Transplant 2007; 7: 1753.
3. Breidenbach WC, Gonzales NR, Kaufman CL, Klapheke M, Tobin GR, Gorantla VS,. Outcomes of the first 2 American hand transplants at 8 and 6 years posttransplant. J Hand Surg Am 2008; 33: 1039.
4. Landin L, Cavadas PC, Nthumba P, Ibanez J, Vera-Sempere F,. Preliminary results of bilateral arm transplantation. Transplantation 2009; 88: 749.
5. Brandacher G, Ninkovic M, Piza-Katzer H, et al,. The Innsbruck hand transplant program: update at 8 years after the first transplant. Transplant Proc 2009; 41: 491.
6. Petruzzo P, Kanitakis J, Badet L, et al,. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant 2012; 11: 808.
7. Petruzzo P, Lanzetta M, Dubernard JM, et al,. The International Registry on Hand and Composite Tissue Transplantation. Transplantation 2010; 90: 1590.
8. Schneeberger S, Landin L, Jableki J, et al,. Achievements and challenges in composite tissue allotransplantation. Transpl Int 2011; 24: 760.
9. Landin L, Bonastre J, Casado-Sanchez C, et al,. Outcomes with respect to disabilities of the upper limb after hand allograft transplantation: a systematic review. Transpl Int 2012; 25: 424.
10. Schneeberger S, Lucchina S, Lanzetta M, et al,. Cytomegalovirus-related complications in human hand transplantation. Transplantation 2005; 80: 441.
11. Bonatti H, Brandacher G, Margreiter R, Schneeberger S,. Infectious complications in three double hand recipients: experience from a single center. Transplant Proc 2009; 41: 517.
12. Landin L, Cavadas PC, Ibanez J, Roger I,. Malignant skin tumor in a composite tissue (bilateral hand) allograft recipient. Plast Reconstr Surg 2010; 125: 20e.
13. Hettiaratchy S, Melendy E, Randolph MA, et al,. Tolerance to composite tissue allografts across a major histocompatibility barrier in miniature swine. Transplantation 2004; 77: 514.
14. Lee WP, Yaremchuk MJ, Pan YC, Randolph MA, Tan CM, Weiland AJ,. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg 1991; 87: 401.
15. Schneeberger S, Kreczy A, Brandacher G, Steurer W, Margreiter R,. Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H. Am J Transplant 2004; 4: 1372.
16. Schneeberger S, Gorantla VS, van Riet RP, et al,. Atypical acute rejection after hand transplantation. Am J Transplant 2008; 8: 688.
17. Kanitakis J, Jullien D, Petruzzo P, et al,. Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation 2003; 76: 688.
18. Kanitakis J, Petruzzo P, Jullien D, et al,. Pathological score for the evaluation of allograft rejection in human hand (composite tissue) allotransplantation. Eur J Dermatol 2005; 15: 235.
19. Cahalan MD, Wulff H, Chandy KG,. Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol 2001; 21: 235.
20. Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD,. K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci 2004; 25: 280.
21. Wulff H, Calabresi PA, Allie R, et al,. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest 2003; 111: 1703.
22. Beeton C, Wulff H, Standifer NE, et al,. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 2006; 103: 17414.
23. Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H,. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 2007; 127: 1419.
24. Beeton C, Barbaria J, Giraud P, et al,. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol 2001; 166: 936.
25. Fasth AE, Cao D, van Vollenhoven R, Trollmo C, Malmstrom V,. CD28nullCD4+ T cells-characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Immunol 2004; 60: 199.
26. Beeton C, Pennington MW, Wulff H, et al,. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 2005; 67: 1369.
27. Schmitz A, Sankaranarayanan A, Azam P, et al,. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 2005; 68: 1254.
28. Koo GC, Blake JT, Talento A, et al,. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol 1997; 158: 5120.
29. Felix JP, Bugianesi RM, Schmalhofer WA, et al,. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry 1999; 38: 4922.
30. Koo GC, Blake JT, Shah K, et al,. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol 1999; 197: 99.
31. Hautz T, Zelger B, Grahammer J, et al,. Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. Am J Transplant 2010; 10: 1200.
32. Kanitakis J, Badet L, Petruzzo P, et al,. Clinicopathologic monitoring of the skin and oral mucosa of the first human face allograft: report on the first eight months. Transplantation 2006; 82: 1610.
33. Sacks JM, Kuo YR, Horibe EK, et al,. An optimized dual-surgeon simultaneous orthotopic hind-limb allotransplantation model in rats. J Reconstr Microsurg 2012; 28: 69.
34. Solari MG, Washington KM, Sacks JM, et al,. Daily topical tacrolimus therapy prevents skin rejection in a rodent hind limb allograft model. Plast Reconstr Surg 2009; 123 (2 Suppl.): 17S.
35. Seger C, Tentschert K, Stoggl W, Griesmacher A, Ramsay SL,. A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples. Nat Protoc 2009; 4: 526.
36. Hyodo T, Oda T, Kikuchi Y, et al,. Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol 2010; 299: F1258.
37. Ghanshani S, Wulff H, Miller MJ, et al,. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 2000; 275: 37137.
38. Gilhar A, Bergman R, Assay B, Ullmann Y, Etzioni A,. The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model. J Invest Dermatol 2011; 131: 118.
39. Matheu MP, Beeton C, Garcia A, et al,. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 2008; 29: 602.
40. Wang B, Amerio P, Sauder DN,. Role of cytokines in epidermal Langerhans cell migration. J Leukoc Biol 1999; 66: 33.
41. Biedermann T, Kneilling M, Mailhammer R, et al,. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000; 192: 1441.